NASDAQ:IOVA
Iovance Biotherapeutics, Inc. Stock News
$13.63
+0.750 (+5.82%)
At Close: May 03, 2024
Why Iovance Stock Leaped 17% Higher Today
06:52pm, Friday, 03'rd Jun 2022
Several insiders have been purchasing the company's common shares lately.
Insiders Buy Around $10M Of 3 Stocks
11:53am, Friday, 03'rd Jun 2022 Benzinga
Although the Dow Jones jumped more than 400 points on Thursday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that
Biotech stocks get a boost, or plunge, as new clinical data is shared before major cancer meeting
12:54pm, Sunday, 29'th May 2022 MarketWatch
This includes Arcellx, Iovance Biotherapeutics, and ZymeWorks.
Iovance (IOVA) Down After Announcing Data From Melanoma Study
06:43pm, Friday, 27'th May 2022 Zacks Investment Research
Results from a cohort of the phase II study evaluating Iovance's (IOVA) melanoma candidate were not as superior as data from another cohort of the same study.
Why Iovance Biotherapeutics Was Halved Today
05:08pm, Friday, 27'th May 2022 The Motley Fool
Investors are seeing the proverbial glass as half-empty rather than half-full.
Iovance (IOVA) Down After Announcing Data From Melanoma Study
03:49pm, Friday, 27'th May 2022
Results from a cohort of the phase II study evaluating Iovance's (IOVA) melanoma candidate were not as superior as data from another cohort of the same study.
Why Iovance Biotherapeutics Was Halved Today
01:08pm, Friday, 27'th May 2022
Investors are seeing the proverbial glass as half-empty rather than half-full.
Even this pessimistic Bank of America strategist says the bear-rally bandwagon has room to charge ahead
12:43pm, Friday, 27'th May 2022 MarketWatch
Michael Hartnett said there will be a point to fade the S&P 500 rally. But not yet.
Why Is Iovance Therapeutics (IOVA) Stock Down 45% Today?
10:41am, Friday, 27'th May 2022
Iovance Therapeutics (IOVA) stock is falling hard on Friday following the release of clinical trial data for its melanoma treatment. The post Why Is Iovance Therapeutics (IOVA) Stock Down 45% Today?
Iovance Biotherapeutics Announces Positive Clinical Data for Lifileucel in Advanced Melanoma
08:01pm, Thursday, 26'th May 2022 GlobeNewswire Inc.
Positive Results in Advanced Melanoma Patients, Including a 29% Objective Response Rate (ORR) in Cohort 4 of the C-144-01 Study
4 Analysts Have This to Say About Iovance Biotherapeutics
04:09pm, Tuesday, 24'th May 2022 Benzinga
Within the last quarter, Iovance Biotherapeutics (NASDAQ:IOVA) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
2
2
0
0
Why Cellectis' Shares Rose 22.7% This Week
11:35pm, Friday, 20'th May 2022 The Motley Fool
The company bucked the recent downward trend for biotech companies.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
09:15pm, Friday, 20'th May 2022 GlobeNewswire Inc.
SAN CARLOS, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today anno
Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track
02:45pm, Friday, 06'th May 2022 Zacks Investment Research
Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.
Iovance (IOVA) Q1 Earnings Beat, Lifileucel BLA on Track
12:02pm, Friday, 06'th May 2022
Iovance Biotherapeutics (IOVA) reports a narrower-than-expected first-quarter loss. The company is on track to file a regulatory submission for lifileucel in melanoma in August 2022.
